TY - JOUR
T1 - Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement
AU - Rodenhuis, Sjoerd
AU - Richel, Dick J.
AU - Van Der Wall, Elsken
AU - Schornagel, Jan H.
AU - Baars, Joke W.
AU - Koning, Caro C.E.
AU - Peterse, Johannes L.
AU - Borger, Jacques H.
AU - Nooijen, Willem J.
AU - Bakx, Roel
AU - Dalesio, Otilia
AU - Rutgers, Emiel
N1 - Funding Information:
This study was supported in part by a grant from the Schumacher-Kramer Foundation, Amsterdam, Netherlands.
PY - 1998/8/15
Y1 - 1998/8/15
N2 - Background. Uncontrolled studies suggest that high-dose chemotherapy is beneficial in patients with breast cancer and multiple metastases to the axillary lymph nodes. Many physicians accept this treatment as standard care. We aimed to assess adjuvant high-dose chemotherapy in breast cancer in a phase II randomised trial. Methods. 97 women aged younger than 60 years, who had breast cancer with extensive axillary-node metastases (confirmed by a tumour-positive infraclavicular lymph-node biopsy), received three courses of up-front chemotherapy (FE120C). This regimen consisted of cyclophosphamide 500 mg/m2, epirubicin 120 mg/m2, and 5-fluorouracil 500 mg/m2 once weekly for 3 weeks. After surgery, stable patients or those who responded to chemotherapy were randomly assigned conventional therapy (fourth course of FE120C, followed by radiation therapy and 2 years of tamoxifen [40 patients]) or high-dose therapy (identical treatment but an additional high-dose regimen and peripheral-blood progenitor-cell [PBPC] support after the fourth FE120C course [41 patients]). This high-dose regimen comprised cyclophosphamide 6 g/m2, thiotepa 480 mg/m2, and carboplatin 1600 mg/m2. The primary endpoint was overall and disease-free survival. All analyses were by intention to treat. Findings. No patients died from toxic effects of chemotherapy. With a median follow-up of 49 (range 21-76) months, the 4-year overall and relapse-free survivals for all 97 patients were 75% and 54% respectively. There was no significant difference in survival between the patients on conventional therapy and those on high-dose therapy. Interpretation. High-dose therapy is associated with substantial cost and acute toxic effects, but also has potentially irreversible long-term effects. Until the benefit of this therapy is substantiated by large-scale phase III trials, high-dose chemotherapy should not be used in the adjuvant treatment of breast cancer, apart from in randomised studies.
AB - Background. Uncontrolled studies suggest that high-dose chemotherapy is beneficial in patients with breast cancer and multiple metastases to the axillary lymph nodes. Many physicians accept this treatment as standard care. We aimed to assess adjuvant high-dose chemotherapy in breast cancer in a phase II randomised trial. Methods. 97 women aged younger than 60 years, who had breast cancer with extensive axillary-node metastases (confirmed by a tumour-positive infraclavicular lymph-node biopsy), received three courses of up-front chemotherapy (FE120C). This regimen consisted of cyclophosphamide 500 mg/m2, epirubicin 120 mg/m2, and 5-fluorouracil 500 mg/m2 once weekly for 3 weeks. After surgery, stable patients or those who responded to chemotherapy were randomly assigned conventional therapy (fourth course of FE120C, followed by radiation therapy and 2 years of tamoxifen [40 patients]) or high-dose therapy (identical treatment but an additional high-dose regimen and peripheral-blood progenitor-cell [PBPC] support after the fourth FE120C course [41 patients]). This high-dose regimen comprised cyclophosphamide 6 g/m2, thiotepa 480 mg/m2, and carboplatin 1600 mg/m2. The primary endpoint was overall and disease-free survival. All analyses were by intention to treat. Findings. No patients died from toxic effects of chemotherapy. With a median follow-up of 49 (range 21-76) months, the 4-year overall and relapse-free survivals for all 97 patients were 75% and 54% respectively. There was no significant difference in survival between the patients on conventional therapy and those on high-dose therapy. Interpretation. High-dose therapy is associated with substantial cost and acute toxic effects, but also has potentially irreversible long-term effects. Until the benefit of this therapy is substantiated by large-scale phase III trials, high-dose chemotherapy should not be used in the adjuvant treatment of breast cancer, apart from in randomised studies.
UR - http://www.scopus.com/inward/record.url?scp=7344254625&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=7344254625&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(98)01350-6
DO - 10.1016/S0140-6736(98)01350-6
M3 - Article
C2 - 9716055
AN - SCOPUS:7344254625
SN - 0140-6736
VL - 352
SP - 515
EP - 521
JO - Lancet
JF - Lancet
IS - 9127
ER -